1Schnieder, JS, Reynolds, CF, Lebowitz, BD, Friedhoff, AJ. Diagnosis and treatment of depression in later life. Washington, DC: American Psychiatric Press, 1994.
2Lapin, IP, Oxenkrug, GF. Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. Lancet 1969; i: 132–36.
3Meltzer, HY, Lowy, MT. The serotonin hypothesis of depression. In: Meltzer, HY ed. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987: 513–26.
4Koenig, HG, Blazer, DG. Epidemiology of geriatric affective disorders. Clin Geriatric Med 1992; 8: 235–51.
5Snowdon, J. The prevalence of depression in old age. Int J Geriatric Psychiatry 1990; 5: 141–44.
6Rovner, BW, German, PS, Brant, LJ et al. Depression and mortality in nursing homes. JAMA 1991; 265: 993–96.
7Blazer, D. Depression in the elderly. N Engl J Med 1989; 320: 164–66.
8Sulser, F, Janowsky, AJ, Okada, F, Manier, DH, Mobley, PL. Regulation of recognition and action function of norepinephrine (NE) receptor-coupled adenylate cyclase system in brain: implications for the therapy of depression. Neuropharmacology 1983; 22: 425–31.
9Guthrie, SK. Sertraline: a new specific serotonin reuptake blocker. DICP, Ann Pharmacother 1991; 25: 952–61.
10Stark, P, Fulle, RW, Wong, DT. The pharmacologic profile of fluoxetine. J Clin Psychiatry 1985; 46: 7–13.
11Pujol, JF, Keane, P, McRae, A et al. Biochemical evidence for serotonergic control of the locus ceruleus. In: Garatinni, S, Pujol, JF, Samanin, R eds. Interactions between putative neurotransmitters in the brain. New York: Raven Press, 1978: 401–10.
12Wang, RY, Aghajanian, GK. Collateral inhibition of serotonergic neurons in the dorsal raphe nucleus: pharmacological evidence. Neuropharmacology 1987; 17: 819–25.
13Feuerstein, TJ, Hertting, G. Serotonin (5-HT) enhances hippocampal noradrenaline (NA) release: evidence for facilitatory 5-HT receptors within the CNS. Naunyn Schmiedebergs Arch Pharmacol 1986; 333: 191–97.
14Doogan, DP, Callard, V. Sertraline: a new antidepressant. J Clin Psychiatry 1988; 49 (suppl 8): 46–51.
15Shopsin, B, Friedman, E, Gershon, S. Pharachlorphenylalanine reversal of tranylcypramine effects in depressed patients. Arch Gen Psychiatry 1976; 33; 811–19.
16Grimsley, SR, Jann, MW. Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Clin Pharmacy 1992; 11: 930–57.
17Lemberger, L, Bergstrom, RF, Wolen, RL et al. Fluoxetine: clinical pharmacology and physiologic disposition. J Clin Psychiatry 1985; 46: 14–19.
18Bergstrom, RF, Lemberger, L, Farid, NA, Wolen, RL. Clinical pharmacology and pharmacokinetics of fluoxetine: a review. Br J Psychiatry 1988; 153 (suppl 3): 47–50.
19Mellerup, ET, Plenge, P. High affinity binding of 3H-paroxetine and 3H-imipramine to rat neuronal membranes. Psychopharmacology 1986; 89: 436–39.
20Preskorn, SH. Recent pharmacologic advances in antidepressant therapy for the elderly. Am J Med 1993; 2(94): 2S–12S.
21Bayer, AJ, Roberts, NA, Allen, EA et al. The pharmacokinetics of paroxetine in the elderly. Acta Psychiatr Scand 1989; 80 (suppl 350): 85–86.
22Lundmark, J, Thomsen, IS, Fjord-Larsen, T et al. Paroxetine: pharmacokinetic and antidepressant effect in the elderly. Acta Psychiatr Scand 1989; 80 (suppl 350): 76–80.
23Haddock, RE, Johnson, AM, Langley, PF et al. Metabolic pathway of paroxetine in animals and man and the comparative pharmacological properties of its metabolites. Acta Psychiatr Scand 1989; 80 (suppl 350): 24–26.
24Kaye, CM, Haddock, RE, Langley, PF et al. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand 1989; 80 (suppl 350): 60–75.
25Tasker, TCG, Kaye, CM, Zussman, BD, Link, CGG. Paroxetine plasma levels: lack of correlation with efficacy or adverse events. Acta Psychiatr Scand 1989; 80 (suppl 350): 152–55.
26Koe, BK. Preclinical pharmacology of sertraline: a potent and specific inhibitor of serotonin reuptake. J Clin Psychiatry 1990; 51 (suppl B): 13–17.
27Johnson, AM. An overview of the animal pharmacology of paroxetine. Acta Psychiatr Scand 1989; 80 (suppl 350): 14–20.
28Dunbar, GC. An interim overview of the safety and tolerability of paroxetine. Acta Psychiatr Scand 1989; 80 (suppl 350): 135–37.
29Schmidt, MJ, Fuller, RW, Wong, DT. Fluoxetine, a highly selective serotonin reuptake inhibitor: a review of preclinical studies. Br J Psychiatry 1988; 153 (suppl 3): 40–46.
30Fredericson, O-K. Kinetics of citalopram in elderly patients. Psychopharmacology 1985; 86: 253–57.
31Schatzberg, AF. Dosing strategies for antidepressant agents. J Clin Psychiatry 1991; 52 (5 suppl): 14–20.
32Altamura, AC, Montgomery, SA, Wernicke, JF. The evidence for 20 mg a day of fluoxetine as the optimal dose in the treatment of depression. Br J Psychiatry 1988; 153 (suppl 3): 109–12.
33Salzman, C. Monoamine oxidase inhibitors and atypical antidepressants. Clin Geriatric Med 1992; 8: 335–48.
34Guthrie, SK. Sertraline: a new specific serotonin reuptake blocker. DICP, Ann Pharmacother 1991; 25: 952–61.
35Berman, I, Sapers, BL, Salzman, C. Sertraline: a new sertonergic antidepressant. Hosp Commun Psychiatry 1992; 43: 671–72.
36Jenner, PN. Paroxetine: an overview of dosage, tolerability, and safety. Int Clin Psychopharmacol 1992; 6 (suppl 4): 69–80.
37Feighner, JP, Cohn, JB. Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. J Clin Psychiatry 1985; 46(3): 20–25.
38Feighner, JP, Boyer, WF, Meredith, CH, Hendrickson, G. An overview of fluoxetine in geriatric depression. Br J Psychiatry 1988; 153 (suppl 3): 105–108.
39Altamura, AC, de Novellis, F, Guercetti, G et al. Fluoxetine compared with amitriptyline in elderly depression: a controlled clinical trial. Int J Clin Pharmacol Res 1989; IX: 391–96.
40Conn, CK, Shrivastava, R, Mendels, J et al. Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. J Clin Psychiatry 1990; 51 (12 suppl): 28–33.
41Dunner, DL, Cohn, JB, Walshe, T III et al. Two combined, multi-centre double-blind studies of paroxetine and doxepin in geriatric patients with major depression. J Clin Psychiatry 1992; 53 (suppl 2): 57–60.
42Guillibert, E, Pelicier, Y, Archambault, JC et al. A double-blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients. Acta Psychiatr Scand 1989; 80 (suppl 350): 132–34.
43Wakelin, JS. Fluvoxamine in the treatment of the older depressed patient: double-blind, placebo-controlled data. Int Clin Psychopharmacol 1986; 1: 221–30.
44Phanjoo, AL, Wonnacott, S, Hodgson, A. Double-blind comparative multicentre study of fluvoxamine and mianserin in the treatment of major depressive episode in elderly people. Acta Psychiatr Scand 1991; 83: 476–79.
45Schone, W, Ludwig, M. A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. J Clin Psychopharmacol 1993; 13 (6 suppl 2): 34S–39S.
46Wagner, W, Plekkenpol, B, Gray, TE. Review of fluvoxamine safety database. Drugs 1992; 43 (suppl 2): 48–54.
47Benfield, P, Ward, A. Fluvoxamine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986; 32: 313–34.
48Howard, R, Bandyopadhyay, D. Selective serotonin reuptake inhibitors for the elderly. Int J Geriatric Psychiatry 1992; 8: 627–29.
49Reimherr, FW, Chouinard, G, Cohn, CK et al. Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry 1990; 51 (12 suppl B): 18–27.
50Heym, J, Koe, BK. Pharmacology of sertraline: a review. J Clin Psychiatry 1988; 49 (8 suppl): 40–45.
51Wurtman, JJ, Wurtman, RJ. Fenfluramine and fluoxetine spare protein consumption while suppressing caloric intake by rats. Science 1977; 198: 1178–80.
52Crews, J, Potts, N, Schreiber, J, Lipper, J. Hyponatremia in a patient treated with sertraline [Letter]. Am J Psychiatry 1993; 150: 1517.
53Belanoff, J, Sheikh, JI. Hyponatremia as a side effect of selective serotonin reuptake inhibitors. Am J Geriatric Psychiatry 1994 (in press).
54Feighner, JP, Boyer, WF. Paroxetine in the treatment of depression: a comparison with imipramine and placebo. Acta Psychiatr Scand 1989; 80 (suppl 350): 125–29.
55Wurtman, JJ. Discussion: conference on sertraline. J Clin Psychiatry 1988; 49 (8 suppl): 72–73.
56Cooper, GL. The safety of fluoxetine – an update. Br J Psychiatry 1988; 153 (suppl 3): 77–86.
57Byerley, WF, Reimherr, FW, Wood, DR. Fluoxetine, a selective serotonin uptake inhibitor for the treatment of outpatients with major depression. J Clin Psychopharmacol 1988; 8: 112–15.
58Cole, JO. New directions in antidepressant therapy: a review of sertraline, a unique serotonin reuptake inhibitor. J Clin Psychiatry 1992; 53: 333–40.
59Cole, JO, Bodkin, JA. Antidepressant drug side effects. J Clin Psychiatry 1990; 51 (1 suppl): 21–26.
60Schweizer, E, Rickeis, K. Clinical overview of serotonin reuptake inhibitors. J Clin Psychiatry 1990; 51 (12 suppl B): 9–12.
61Fisch, C. Effect of fluoxetine on the electrocardiogram. J Clin Psychiatry 1985; 46: 42–44.
62Buff, DD, Brenner, R, Kirtane, SS, Gilboa, R. Dysrhythmia associated with fluoxetine treatment in an elderly patient with cardiac disease. J Clin Psychiatry 1991; 52: 174–76.
63Ellison, JM, Milogsky, JE, Ely, E. Fluoxetine-induced bradycardia and syncope in two patients. J Clin Psychiatry 1990; 51: 385–86.
64Halper, JP, Mann, JJ. Cardiovascular effects of antidepressant medications. Br J Psychiatry 1988; 152 (suppl 3): 87–98.
65Wernicke, JF. The side effect profile and safety of fluoxetine. J Clin Psychiatry 1985; 46: 59–67.
66Mattila, MJ, Saarialho-Kere, U, Manila, M. Acute effects of sertraline, amitriptyline, and placebo on the psychomotor performance of healthy subjects over 50 years of age. J Clin Psychiatry 1988; 49 (8 suppl): 52–58.
67Musher, JS. Anorgasmia with the use of fluoxetine [Letter]. Am J Psychiatry 1990; 147: 948.
68Smith, D, Levitte, S. Association of fluoxetine and return of sexual potency in three elderly men. J Clin Psychiatry 1993; 54: 317–19.
69Hwang, AS, Magraw, RM. Syndrome of inappropriate secretion of antidiuretic hormone due to fluoxetine [Letter]. Am J Psychiatry 1989; 146: 399.
70Cohen, JB, Mahelsky, M, Adler, L [Letter]. More cases of SIADH with fluoxetine. Am J Psychiatry 1990; 147: 948–49.
71Gommare, JH, Edwards, RA. Fluoxetine and hyponatremia [Letter]. N Z Med J 1990; 105: 106.
72Vishvanuth, B, Navalgund, AA, Cosano, W, Nagaland, HA. Fluoxetine as a cause of SIADH [Letter]. Am J Psychiatry 1991; 148: 542–43.
73Goddard, C, Paton, C. Hyponatremia associated with paroxetine [Letter]. BMJ 1993; 306: 143.
74Chun, TP, Vong, SH. Hyponatremia associated with paroxetine [Letter]. BMJ 1993; 306: 143.
75Lipinski, JF Jr, Mallya, G, Zimmerman, P et al. Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry 1989; 50: 339–42.
76Rothschild, AJ, Locke, CA. Re-exposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. J Clin Psychiatry 1991; 52: 491–93.
77Black, B, Uhde, TW [letter]. Acute dystonia and fluoxetine. J Clin Psychiatry 1992; 53: 327.
78Bouchard, RH, Pourcher, E, Vincent, P. Fluoxetine and extra-pyramidal side effects [Letter]. Am J Psychiatry 1989; 146: 1352–53.
79Baldwin, D, Fineberg, N, Montgomery, S. Fluoxetine, fluvoxamine, and extra-pyramidal disorders. Int Clin Psychopharmacol 1991; 6: 51–58.
80Hebenstreit, GF, Fellerer, K, Zochling, R, Zentz, A, Dunbar, GC. A pharmacokinetic dose titration study in adult and elderly depressed patients. Acta Psychiatr Scand 1989; 80 (suppl 350): 81–84.
81Chouinard, G, Jones, B. No crossover of hypersensitivity between zimelidine and fluoxetine. Can Med Assoc J 1984; 131: 1190.
82Figiel, GS, Krishnan, KRR, Breitner, JC, Nemeroff, CB. Radiologic correlates of antidepressant-induced delirium: the possible significance of basal-ganglia lesions. J Neuropsychiatry 1989; 1: 188–90.
83Hindmarsh, I, Shillingford, J, Shillingford, C. The effects of sertraline on psychomotor performance in elderly volunteers. J Clin Psychiatry 1990; 51 (12 suppl B): 34–36.
84Hindmarch, I, Harrison, C. The effects of paroxetine and other antidepressants in combination with alcohol on psychomotor activity related to car driving. Acta Psychiatr Scand 1989; 80 (suppl 350): 45–49.
85Sternbach, H. Danger of MAOI therapy after fluoxetine withdrawal. Lancet 1988; ii: 850–51.
86Dursun, S, Mathew, VM, Reveley, MA. Toxic serotonin syndrome after fluoxetine plus carbamazepine [Letter]. Lancet 1993; 342: 442–43.
87Pearson, H. Interaction of fluoxetine with carbamazepine [letter]. J Clin Psychiatry 1990; 51: 126.
88Cowen, P, Thompson, C, Roberts, A et al. Selective serotonin reuptake inhibitors. BMJ 1994; 309: 1082–85.